- Home
- NRXP vs GDTC Comparison
NRXP vs GDTC Comparison
Compare NRXP & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- GDTC
- Stock Information
- Founded
- NRXP 2015
- GDTC 2018
- Country
- NRXP United States
- GDTC Singapore
- Employees
- NRXP N/A
- GDTC N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- GDTC Health Care
- Exchange
- NRXP Nasdaq
- GDTC Nasdaq
- Market Cap
- NRXP 32.6M
- GDTC 28.0M
- IPO Year
- NRXP N/A
- GDTC 2023
- Fundamental
- Price
- NRXP $3.06
- GDTC $2.02
- Analyst Decision
- NRXP Strong Buy
- GDTC Buy
- Analyst Count
- NRXP 4
- GDTC 1
- Target Price
- NRXP $28.50
- GDTC $5.00
- AVG Volume (30 Days)
- NRXP 193.0K
- GDTC 6.7K
- Earning Date
- NRXP 08-13-2025
- GDTC 01-01-0001
- Dividend Yield
- NRXP N/A
- GDTC N/A
- EPS Growth
- NRXP N/A
- GDTC N/A
- EPS
- NRXP N/A
- GDTC N/A
- Revenue
- NRXP N/A
- GDTC $368,838.00
- Revenue This Year
- NRXP N/A
- GDTC $5.37
- Revenue Next Year
- NRXP N/A
- GDTC N/A
- P/E Ratio
- NRXP N/A
- GDTC N/A
- Revenue Growth
- NRXP N/A
- GDTC N/A
- 52 Week Low
- NRXP $1.10
- GDTC $1.20
- 52 Week High
- NRXP $6.01
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- NRXP 44.37
- GDTC 39.85
- Support Level
- NRXP $3.03
- GDTC $2.09
- Resistance Level
- NRXP $3.53
- GDTC $2.22
- Average True Range (ATR)
- NRXP 0.17
- GDTC 0.09
- MACD
- NRXP -0.06
- GDTC -0.01
- Stochastic Oscillator
- NRXP 4.95
- GDTC 0.00
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.